Comparing Effect of Double Dose of Hepatitis B Vaccine Verses Conventional Dose in Patients with Chronic Liver Disease

Abstract

Objective: To compare the effectiveness of double dose hepatitis B vaccine in patients with chronic liver disease versus conventional-dose
Study design: Randomized control trial
Place and Duration:  Six months after the approval of synopsis i.e 15th March 2017 to 14th September 2017, Department of General Medicine, FFH, Rawalpindi
Methodology: A total of one hundred and sixteen (n=116) diagnosed cases of chronic liver disease of either gender between age 30 to 70 years were enrolled and were divided into two groups one received a double dose (2 ml, 40 µg) and the other received a conventional dose (1 ml, 20 µg). Quantitative anti-HBs was measured at three months in both groups.  

Mean with standard deviation calculated for quantitative variables like age, anti-HBs level one month after 3rd dose and frequency and percentages in case of categorical variables like gender and effectiveness. Chi-square test was used to determine the significant difference in both groups regarding the effectiveness of vaccination. A p-value ≤0.05 was taken significantly.
Results: In patients who received double dose seroprotection (anit HBs >10 IU/ml) was achieved in 93.1% (n=54/58) patients, while the percentage was 77.6% (n=45/58) in patients who received a conventional dose (P<0.05).
Conclusions: Seroprotection (anit HBs >10 IU/ml) at three months was significantly better in patients who received the double dose of vaccine. Vaccine effectiveness was significantly better in younger age group.